HB+ is proud to partner with the National Minority Health Association to help bring about health equity and close the disparity gap in health and healthcare for underserved, marginalized, hard-to-reach, and minority communities.

A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia and Non-Hodgkin lymphoma whose disease has stopped responding to standard treatments.